Hyderabad, March 5 -- Granules India Limited on Thursday said its US step-down subsidiary Granules Consumer Health, LLC has received an Establishment Inspection Report (EIR) with a No Action Indicated (NAI) status from the U.S. Food and Drug Administration following a recent inspection.
The FDA conducted the inspection at the company's packaging facility in Manassas, Virginia from December 1 to 3, 2025, the Hyderabad based pharmaceutical company said in a release here.
This was the facility's second FDA inspection, after a March 2023 audit that also concluded with zero observations.
Dr. Krishna Prasad Chigurupati, Chairman and Managing Director of Granules India, said the achievement reflects the company's strong quality and regulatory s...